DarioHealth Corp. (NASDAQ:DRIO) Stock Has Consensus Price Target of $9.00 According to Brokerages

Shares of DarioHealth Corp. (NASDAQ:DRIO) have received a consensus recommendation of “Hold” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $9.00.

A number of equities analysts have issued reports on the company. BTIG Research began coverage on DarioHealth in a research note on Tuesday. They set a “buy” rating and a $6.00 price target for the company. TD Cowen lowered their price objective on DarioHealth from $11.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, August 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research note on Tuesday, October 6th. Finally, Alliance Global Partners started coverage on DarioHealth in a report on Wednesday, August 19th. They issued a “buy” rating and a $12.00 target price on the stock.

DarioHealth Stock Down 9.8%

DarioHealth stock opened at $3.40 on Tuesday. The firm has a market capitalization of $33.32 million, a price-to-earnings ratio of -0.55 and a beta of 1.18. The firm’s fifty day moving average price is $6.30 and its two-hundred day moving average price is $7.97. DarioHealth has a 1-year low of $3.01 and a 1-year high of $16.44. The company has a current ratio of 2.31, a quick ratio of 1.92 and a debt-to-equity ratio of 0.56.

DarioHealth (NASDAQ:DRIO) last posted its earnings results on Tuesday, August 11th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.37. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. The company had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.92 million. On average, equities research analysts predict that DarioHealth will post -2.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DarioHealth

An institutional investor recently bought a new stake in DarioHealth stock. BlackRock Inc. acquired a new stake in shares of DarioHealth Corp. (NASDAQ:DRIO) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 37,796 shares of the company’s stock, valued at approximately $249,000. BlackRock Inc. owned approximately 0.51% of DarioHealth at the end of the most recent quarter. 33.39% of the stock is owned by hedge funds and other institutional investors.

DarioHealth Company Profile

DarioHealth Corp. is a digital health company that develops technology-enabled solutions for managing chronic conditions. Its platform combines connected medical devices, mobile applications, data analytics and personalized coaching to help individuals monitor and improve their health.

The company’s offerings have focused on conditions including diabetes, hypertension, musculoskeletal disorders and behavioral health. Products and services may include connected blood glucose and blood pressure monitoring, digital programs for pain and mobility management, health coaching, educational content and tools that support healthier daily habits.